Clinical Research
Copyright ©2005 Baishideng Publishing Group Inc.
World J Gastroenterol. Nov 21, 2005; 11(43): 6792-6799
Published online Nov 21, 2005. doi: 10.3748/wjg.v11.i43.6792
Table 2 Clinical characteristics of BCAA and placebo groups
BCAA groupPlacebo group
Age (yr)64 ± 9(50 - 72)65 ± 8(51 - 74)
Sex ratio, M/F10/69/4
Etiology of cirrhosis, HBV/HCV/unknown1/11/40/12/1
Previous history of overt hepatic encephalopathy, None/Chronic14/212/1
Child-Pugh score8.1 ± 2.5(5 - 13)7.8 ± 2(5 - 11)
Laboratory examinations
Platelet (104µL)8.3 ± 6.8(3.4 - 31.4)7.6 ± 3.1(2.8 – 12.3)
Albumin (g/dL)2.8 ± 0.5(2.1 - 3.9)2.9 ± 0.4(2.4 - 3.9)
Total bilirubin (mg/dL)2.2 ± 3.2(0.8 - 13.8)1.9 ± 1.8(0.5 – 6.9)
Cholinesterase (∆pH)0.32 ± 0.16(0.12 - 0.64)0.38 ± 0.12(0.17 - 0.55)
Plasma ammonia (µmol/L)35 ± 20(9 - 79)34 ± 18(7 - 74)
Prothrombin time (%)68.9 ± 14.4(31.3 - 93.5)71.1 ± 13.4(51.8 – 89.2)
BCAA to tyrosine ratio3.7 ± 1.2(2.3 - 7)3 ± 1.3(1.3 – 5.6)
Neuropsychological test
Trail making test (s)49 ± 16(34 - 77)50 ± 16(25 - 72)
Digit symbol test (gross point)38 ± 10(21 - 53)37 ± 15(19 - 63)